相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
Carolyn E. Haunschild et al.
FUTURE ONCOLOGY (2020)
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
Patricia E. de Almeida et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer
Yusuke Shimizu et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2019)
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N. Moore et al.
FUTURE ONCOLOGY (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors
Satyen Harish Gohil et al.
ONCOIMMUNOLOGY (2017)
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells
Qiu-Xia Qu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth
Thapi Dharma Rao et al.
ACS CHEMICAL BIOLOGY (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
Danielle L. Bourgeois et al.
CANCER CELL INTERNATIONAL (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
Ming-Ru Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Tao Dao et al.
NATURE BIOTECHNOLOGY (2015)
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
Mahiuddin Ahmed et al.
ONCOIMMUNOLOGY (2015)
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
Thapi D. Rao et al.
PLOS ONE (2015)
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
Tiansuo Zhao et al.
ONCOTARGET (2015)
Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer
Darshan A. Mehta et al.
GYNECOLOGIC ONCOLOGY (2014)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
How do CARs work? Early insights from recent clinical studies targeting CD19
Marco L. Davila et al.
ONCOIMMUNOLOGY (2012)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
Alena A. Chekmasova et al.
CLINICAL CANCER RESEARCH (2010)
Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16
Thapi Dharma Rao et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer
Stefania Bellone et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
New tumor markers: CA125 and beyond
RC Bast et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene
BWT Yin et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin
A Shanker et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2000)
分享论文
